期刊文献+

厄洛替尼治疗晚期肺癌1例

原文传递
导出
摘要 1病例报告患者男,62岁,长期吸烟40年,平均每日20支。缘于2011年1月末因咳嗽、咳痰、乏力、盗汗在当地医院就诊,行胸部X线检查示左肺阴影;CT检查示左上肺占位性病变,经"盐酸莫西沙星"治疗4d,咳嗽、咳痰症状稍减轻。为明确诊治,于2011年2月11日到我院就诊,2月15日在CT引导下经皮肺穿刺活检病理组织学检查示低分化癌浸润,大部分为鳞癌,局部伴有腺癌分化;免疫组化染色显示肿瘤细胞:CK8&18(灶状+),p63(+),CK5(+)。全身骨扫描(ECT)示右侧第7肋、左侧第1~3肋轻度浓聚,不除外骨受累。诊断:左肺腺鳞癌伴骨转移(T2N3M1Ⅳ期)。
作者 彭芬加
机构地区 解放军
出处 《总装备部医学学报》 2014年第2期124-125,共2页 Medical Journal of General Equipment Headquarters
  • 相关文献

参考文献1

二级参考文献16

  • 1Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced multicentre study (lressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
  • 2Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N EnglJ Med, 2005, 353(2): 123-132.
  • 3Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11 (2): 121-128.
  • 4Kim ES, Hirsh V, Mok T, et al. fitinib versus docetaxel in previously treatednon-smallcell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
  • 5Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med, 2010,362(25): 2380-2388.
  • 6Mok TS, Wu YL, Xhongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N EnglJ Med, 2009, 361(10): 947-957.
  • 7Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versuscarboplatin (CBDCA) plus gemcitabine (GEM), in (Shinese advanced nonsmall-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. 3Sth European Society for Medical Oncology Congress; 2010 Oct 8-12; Milan, Italy.
  • 8Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non smallcell lung cancer: is KRAS a useful marker in selecting patients for epi dermal growth factor receptortargeted therapy? J Clin Oncol, 2010, 28(31) 4769-4777.
  • 9Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-ceil lung cancer. J Clin Oncolp 2009, 27 (16): 2653-2659.
  • 10Maruyama R, Wataya H, Seto T, et al. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. Anticancer Research, 2009, 29(10): 4217-4221.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部